Ardia Therapeutics

Ardia Therapeutics is a preclinical-stage biotechnology company focused on the discovery and development of targeted cancer therapies through the DNA Damage Response (DDR) pathway. The company utilizes a proprietary platform to identify synthetic lethal interactions, specifically targeting enzymes that cancer cells rely on to repair DNA damage. Its lead research focuses on small molecule inhibitors of Ubiquitin Specific Peptidase 1 (USP1), which is critical for the survival of certain replication-stressed tumors, including those with BRCA mutations. Ardia's pipeline is currently under an exclusive option and license agreement with Exelixis, aimed at advancing novel DDR candidates into clinical development.